Physician profile
John Spiegel
NPI 1043250947
$1,745.25
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $145 · 2021: $164 · 2022: $369 · 2023: $290 · 2024: $56.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $327.03 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $168.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $166.02 | 2019-2021 | |
| Abbvie INC. | $145.78 | 2022-2023 | Duopa, Botox, Qulipta |
| Emd Serono, INC. | $124.96 | 2019 | |
| Genentech USA, INC. | $123.20 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $120.00 | 2021 | |
| Sk Life Science, INC. | $112.50 | 2022 | |
| Baxter Healthcare | $107.32 | 2021-2024 | Floseal |
| Biogen, INC. | $86.24 | 2019-2023 | Vumerity, Tysabri |
| Amgen INC. | $52.11 | 2019-2023 | Aimovig |
| Terumo Bct, INC. | $46.12 | 2019 | |
| Pfizer INC. | $27.18 | 2023 | |
| Lilly USA, LLC | $22.96 | 2023 | Reyvow, Emgality |
| Eisai INC. | $22.79 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $21.96 | 2024 | Gamunex-C |
| Ucb, INC. | $21.33 | 2019 | |
| Sumitomo Pharma America, INC. | $21.00 | 2023 | Aptiom |
| Genzyme Corporation | $15.85 | 2020 | |
| Celgene Corporation | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Spiegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.